Introduction {#section1-0046958016638804}
============

Medicare Advantage (MA) plans and the Veterans Affairs (VA) health care system assess quality of care using, among other things, standardized Healthcare Effectiveness Data and Information Set (HEDIS) performance measures. Performance data are publicly reported and influence health plan and provider payments, so have material consequences. Little is known, however, about the relative accuracy of HEDIS data for persons receiving care in more than one health care system.

Quality of care performance data in the VA often exceeds that reported from private health care settings generally, and MA plans specifically.^[@bibr1-0046958016638804],[@bibr2-0046958016638804]^ The differences may partially result from dissimilar documentation of care in the data sources used for calculating performance rates. Private plans typically generate performance data using insurance claims or abstracted charts, which may fail to capture the entirety of a patient's care compared with VA's comprehensive electronic health record (EHR).^[@bibr3-0046958016638804][@bibr4-0046958016638804]-[@bibr5-0046958016638804]^ Furthermore, the VA by law cannot bill MA plans for services.^[@bibr6-0046958016638804]^ Therefore, MA plans that rely on claims to measure quality may have limited ability to track care processes that occur in the VA. We examined the agreement between MA and VA quality assessments for a group of dually enrolled Veterans. Our study tested the hypothesis that private health plans underreport quality of care relative to fully integrated delivery systems utilizing a comprehensive EHR.

Methods {#section2-0046958016638804}
=======

We identified dually enrolled individuals sampled for the same MA HEDIS and VA External Peer Review Program (EPRP) HEDIS comparator indicator in either 2008 or 2009. We compared performance rates reported by MA plans and VA and assessed agreement using McNemar test for marginal homogeneity. The unit of analysis was the patient. We also conducted stratified analyses for individuals having at least 10 MA outpatient encounters in the measurement year.

Results {#section3-0046958016638804}
=======

The number of individuals sampled for measurement by both systems in the same year ranged from 249 (cholesterol control in coronary heart disease) to 600 (HbA1c testing in diabetes) ([Table 1](#table1-0046958016638804){ref-type="table"}). Reported VA performance was significantly better than reported MA performance for all 12 measures, with VA's performance advantage ranging from 9.8% (glycosylated hemoglobin \[HbA1c\] \< 7.0% in diabetes) to 54.7% (blood pressure \< 140/90 mm Hg in diabetes). The overall agreement ranged from 38.5% to 62.6%. Performance rates derived from VA and MA aggregate data were 1.6% to 14.3% higher than those reported by VA alone.

###### 

Agreement Between HEDIS Performance Assessments in the VA and Medicare Advantage.

![](10.1177_0046958016638804-table1)

  Condition                HEDIS measure                                       Measure type           n assessed by both VA and MA   Overall rate (VA or MA) (%)   VA rate (%)   MA rate (%)   Difference (VA − MA, %)   Agreement[\*](#table-fn2-0046958016638804){ref-type="table-fn"} (%)
  ------------------------ --------------------------------------------------- ---------------------- ------------------------------ ----------------------------- ------------- ------------- ------------------------- ---------------------------------------------------------------------
  Diabetes                 Annual HbA1c Measured                               Process                600                            99.8                          98.2          59.3          38.9                      57.8
                           HbA1c \< 7%                                         Intermediate outcome   266                            59.8                          45.5          35.7          9.8                       61.7
                           HbA1c \< 9% (Control)                               Intermediate outcome   265                            90.1                          87.5          49.1          38.4                      56.2
                           LDL Cholesterol \< 100 mm Hg                        Intermediate outcome   258                            83.7                          78.3          38            40.3                      48.8
                           BP \< 140/90 mm Hg                                  Intermediate outcome   377                            83.0                          79.6          24.9          54.7                      38.5
                           Retinal Exam                                        Process                587                            92.2                          85.5          40.4          45.1                      41.6
                           LDL Cholesterol Measured                            Process                591                            98.3                          95.6          53.1          33.5                      51.9
                           Renal Testing                                       Process                305                            98.0                          94.1          64.6          29.5                      62.6
  Coronary heart disease   LDL Cholesterol Measured                            Process                253                            99.6                          93.7          63.6          30.1                      58.1
                           LDL Cholesterol \< 100 mg/dL                        Intermediate outcome   249                            83.1                          77.1          28.9          48.2                      39.8
  Cancer screening         Women Age 50-69 Screened for Breast Cancer          Process                289                            93.1                          88.2          39.8          48.4                      41.9
                           Patients Age 50-80 Screened for Colorectal Cancer   Process                292                            91.8                          87.7          52.1          35.6                      56.2

*Note.* HEDIS = Healthcare Effectiveness Data and Information Set; VA = Veterans Affairs; MA = Medicare Advantage; HbA1c = glycosylated hemoglobin; LDL = low-density lipoprotein; BP = blood pressure.

McNemar test *P* \< .01 for all values in the column.

In sensitivity analyses limited to individuals having at least 10 MA outpatient encounters, the VA reported better performance than MA for 11 of the 12 measures (ranging from 9.9% to 35.9%), and overall agreement between VA and MA assessment improved only modestly (ranging from 48.5% to 78.7%) ([Table 2](#table2-0046958016638804){ref-type="table"}).

###### 

Agreement Between HEDIS Performance Assessments in the VA and Medicare Advantage Among Patients With ≥ 10 Medicare Advantage Outpatient Encounters in the Measurement Year.
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Condition                HEDIS measure                                                                                             Measure type           n assessed by both VA and MA   Overall rate (VA or MA) (%)   VA rate (%)   MA rate\   Difference (VA-MA, %)   Agreement[\*](#table-fn4-0046958016638804){ref-type="table-fn"}\
                                                                                                                                                                                                                                       (%)                                (%)
  ------------------------ --------------------------------------------------------------------------------------------------------- ---------------------- ------------------------------ ----------------------------- ------------- ---------- ----------------------- ------------------------------------------------------------------
  Diabetes                 Annual HbA1c Measured[\*](#table-fn4-0046958016638804){ref-type="table-fn"}                               Process                218                            99.5                          95.9          78.9       17.0                    75.7

                           HbA1c \< 7%[\*](#table-fn4-0046958016638804){ref-type="table-fn"}                                         Intermediate Outcome   101                            59.4                          45.5          35.6       9.9                     62.4

                           HbA1c \< 9% (Control)[\*](#table-fn4-0046958016638804){ref-type="table-fn"}                               Intermediate Outcome   100                            84.2                          78.0          49.0       29.0                    59.0

                           LDL Cholesterol \< 100 mg/dL[\*](#table-fn4-0046958016638804){ref-type="table-fn"}                        Intermediate Outcome   98                             79.6                          77.6          45.9       31.7                    64.3

                           BP \< 140/90 mm Hg[\*](#table-fn4-0046958016638804){ref-type="table-fn"}                                  Intermediate Outcome   133                            81.9                          78.2          33.1       45.1                    47.4

                           Retinal Exam[\*](#table-fn4-0046958016638804){ref-type="table-fn"}                                        Process                214                            90.6                          81.8          50.9       30.9                    51.4

                           LDL Cholesterol Measured[\*](#table-fn4-0046958016638804){ref-type="table-fn"}                            Process                215                            98.1                          93.0          72.1       20.9                    68.8

                           Renal Testing[\*](#table-fn4-0046958016638804){ref-type="table-fn"}                                       Process                121                            100.0                         93.4          78.5       14.9                    71.9

  Coronary heart disease   LDL Cholesterol Measured[\*](#table-fn4-0046958016638804){ref-type="table-fn"}                            Process                105                            99.1                          90.5          72.4       18.1                    64.8

                           LDL Cholesterol \< 100 mg/dL[\*](#table-fn4-0046958016638804){ref-type="table-fn"}                        Intermediate Outcome   103                            79.6                          71.8          35.9       35.9                    48.5

  Cancer screening         Women Age 50-69 Screened for Breast Cancer[\*](#table-fn4-0046958016638804){ref-type="table-fn"}          Process                96                             94.8                          88.5          54.2       34.3                    53.1

                           Patients Age 50-80 Screened for Colorectal Cancer[\*](#table-fn4-0046958016638804){ref-type="table-fn"}   Process                109                            92.7                          87.2          61.5       25.7                    63.3
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* HEDIS = Healthcare Effectiveness Data and Information Set; VA = Veterans Affairs; MA = Medicare Advantage; HbA1c = glycosylated hemoglobin; LDL = low-density lipoprotein; BP = blood pressure.

McNemar test *P* \< .01 for all values in the column.

Discussion {#section4-0046958016638804}
==========

The VA classified significantly more patients as having met outpatient performance targets than did MA plans despite assessing the same individuals using identical measure specifications. We observed similar degrees of disagreement for both processes of care and intermediate outcomes.

MA plans primarily use claims-based methods to assess process measures; intermediate outcome assessment typically requires additional chart review. Pawlson and colleagues noted that claims underreport quality relative to approaches using both claims and chart review.^[@bibr5-0046958016638804]^ In addition, plans typically collect quality information from heterogeneous providers in their networks. The VA's system-wide EHR may allow for more complete capture of quality information across multiple providers and settings.^[@bibr3-0046958016638804],[@bibr7-0046958016638804]^ In addition, the VA often includes clinical reminders for providers to document adherence to clinical performance metrics, even when care occurs in non-VA settings.^[@bibr8-0046958016638804]^

Among persons enrolled in both systems, performance rates that integrate information from both VA and MA sources were higher than rates considering information from either system alone. Although we did not validate reported performance rates from either system, our findings suggest that neither MA plans nor the VA fully capture quality of care information for dually enrolled persons. However, the VA may be positioned to report substantially better clinical performance because its documentation is more complete. Further studies should compare the accuracy of publicly reported quality data from insurers and integrated delivery systems, particularly for individuals enrolled in multiple health systems.
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